Compare immune activity and HIV hidden reservoir on two treatments
Part of Immune system & allergy, Infections clinical trials.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 65 years old
- Your HIV infection is confirmed (either positive antibody tests twice or detectable HIV RNA twice on different days)
- You’ve been on the same HIV treatment (ART) for at least 1 year and did not switch in the last 6 months
- Your CD4 count has been over 350 in the last 6 months
- Your viral load has been under 40 copies/mL on at least two tests while staying on ART, with no big “blips” over 1000
- You must be able to consent and attend all required study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study in Uganda looks at the HIV 'reservoir' (where the virus hides in the body) in people whose HIV is already well-controlled with medications. It involves blood draws and genetic testing to learn more about the virus.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.